July 12, 2021

Undervalued and Insider Buying at Riley Financial

 The Fool has noted that Riley Financial CEO has been buying shares over the past year.  Many metrics also show that this company is still undervalued despite its recent run up. 

July 6, 2021

Small Article on Schrodinger

 The Fool has a small article on Schrodinger and why it is one of their highest conviction picks.  The author also notes that OptimizeRX is another one of his high conviction picks. 

July 4, 2021

On Avinger

 

This medical devices company could be a takeover candidate. Avinger Inc. (NASDAQ: AVGR) designs, manufactures and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. Its lumivascular platform integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

In addition, its first-generation chronic total occlusion-crossing catheters, Wildcat and Kittycat 2, employ a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across such an occlusion.

B. Riley Securities has started coverage with a $2.50 price target, which is right in line with the consensus target.